{"entity":{"id":"nct06573398","kind":"trial","name":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","aka":[],"tldr":"A phase 2 trial of tislelizumab in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.","summary":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC is a phase 2, interventional study registered as NCT06573398 by Ruijin Hospital, with a registry enrolment figure of 20 participants, started 2024-09-01 and due to reach its primary completion in 2025-09-01. Interventions recorded: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin. Conditions listed: Carcinoma, Pancreatic Ductal. Primary outcome: R0 resection rate. Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of pancreas;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06573398","url":"https://clinicaltrials.gov/study/NCT06573398"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06573398","phase":"2","setting":"Efficacy and Safety of Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for Borderline Resectable Pancreatic Cancer","sponsor":"Ruijin Hospital","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06573398/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}